Migraine Without Aura Clinical Trial
Official title:
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Verified date | November 2020 |
Source | Beijing University of Chinese Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study recruits 30 subjects into three groups, including two experimental groups and one control group. The two experimental groups receive acupuncture treatment for 4 weeks and two times functional magnetic resonance imaging scans as well as clinical symptom assessments. The control group receive one scan without any intervention. The aim of this study is to find the whether the effect of acupuncture treatment have diversity among migraineurs with different disease course.
Status | Completed |
Enrollment | 30 |
Est. completion date | February 1, 2020 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Fitting to the standard of migraine without aura in the international classification of headache disease (ICHD-2) issued by the international headache society in 2004. - Age from 18 to 55, male or female, with right-handedness. - Having no depression or other serious mental illness. - Having no psychoactive drugs taken in the past 3 months, or vasoactive drugs in the past 2 weeks. - Having no habit of taking analgesics from a long time. Exclusion Criteria: - Having the first headache attack of migraine after 55 years old. - Having a history of head injury, cluster headache, or other unclassified headaches. - Taking medicine to prevent migraine in recent 4 weeks. - Having the serious asymmetry or definite pathological changes in the anatomical structure of the head through the MRI scan. - Cannot hold on the times of the MRI scan. |
Country | Name | City | State |
---|---|---|---|
China | Dongzhimen Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing University of Chinese Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Headache Intensity | The headache intensity is measured by the value of Visual Analogue Scale which limits 1 to 10. The higher value of this scale represents the worse headache. | Change from Visual Analogue Scale at 1 months. | |
Primary | Headache Days | The days when headache attacked. The increased day represents the worse headache. | Change from the number of day at 1 months. | |
Primary | Headache Frequency | The maximum times in one day during the headache attacked. The increased time represents the worse headache. | Change from the times of headache attack at 1 months. | |
Primary | Dataset of functional magnetic resonance imaging on brain | Dataset of functional magnetic resonance imaging on brain includes functional images, structural images and diffusion tensor images. | Changes from the dataset of subject's brain area at 1 months. | |
Secondary | Pittsburgh Sleep Quality Index | One of the clinical measurement. The higher value represents the worse quality of sleep. | Change from the value of Pittsburgh Sleep Quality Index at 1 months. | |
Secondary | Medical Outcomes Study Short-Form 36 questionnaire | One of the clinical measurement. The value range is 0 to 10, the higher value represents the better quality of life. | Change from the value of Medical Outcomes Study Short-Form 36 questionnaire at 1 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01687660 -
Acupuncture for Migraine Prophylaxis
|
N/A | |
Completed |
NCT00363532 -
Functional MRI (fMRI) in CGRP Induced Migraine
|
N/A | |
Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
Completed |
NCT04533568 -
Ibuprofen in Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Completed |
NCT00380263 -
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
|
N/A | |
Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Recruiting |
NCT06414044 -
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
|
||
Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 | |
Recruiting |
NCT04157192 -
Brain Connectome for Acupuncture-treated Migraine Patients
|
N/A |